Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Regulatory Toxicology and Pharmacology : RTP|September 1, 2016
Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new InsightsGuenter Blaich, Andreas Baumann, Sven Kronenberg, et al.
European Journal of Endocrinology|November 18, 2024
Cardiovascular status in endogenous cortisol excess: the prospective CV-CORT-EX studyCaroline Morbach, Mario Detomas, Floran Sahiti, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2015
Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapiesFrank R Brennan, Andreas Baumann, Guenter Blaich, et al.
Protein Science : a Publication of the Protein Society|April 23, 2002
Self-assembly of the hydrophobin SC3 proceeds via two structural intermediatesMarcel L de Vocht, Ilya Reviakine, Wolf-Peter Ulrich, et al.
Neurology|November 13, 2020
Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-BShufan Huo, Nicolle Kränkel, Alexander Heinrich Nave, et al.
Regulatory Toxicology and Pharmacology : RTP|January 23, 2018
Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturingPeter Ulrich, Guenter Blaich, Andreas Baumann, et al.
Molecular Therapy. Methods & Clinical Development|October 7, 2020
Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group PerspectiveMichael W Bolt, Laurence O Whiteley, Jessica L Lynch, et al.
BMC Neurology|March 11, 2017
Stroke unit care in germany: the german stroke registers study group (ADSR)Steffi Hillmann, Silke Wiedmann, Viktoria Rücker, et al.
Journal of the American Heart Association|February 8, 2025
Early Complications After Mild to Moderate Ischemic Stroke and Impact on 3-Month Outcome: The Multicenter Prospective Stroke Unit Plus Cohort StudyJan Sobesky, Vince Istvan Madai, Sarah Zweynert, et al.
Pageof 6